m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02479)
Name
Trimethoprim
Synonyms
Trimanyl; Trimethioprim; Trimethoprime; Trimethoprimum; Trimetoprim; Trimetoprima; Trimopan; Trimpex; Triprim; Trisulcom; Trisulfam; Uretrim; Apo-Sulfatrim; Bacticel; Bactramin; Chemotrin; Cotrimel; Espectrin; Fermagex; Lagatrim; Monoprim; Monotrim; Monotrimin; NIH 204; Novotrimel; Pancidim; Proloprim; Sinotrim; Sugaprim; Sulfamar; Sulfamethoprim; Sulfoxaprim; Syraprim; Urobactrim; Wellcoprim; Wellcoprin; Zamboprim; trimethoprim; 2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine; 5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine; 738-70-5; Abaprim
    Click to Show/Hide
Status
Approved
Structure
Formula
C14H18N4O3
InChI
1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
InChIKey
IEDVJHCEMCRBQM-UHFFFAOYSA-N
PubChem CID
5578
VARIDT Drug ID
DR00590
INTEDE Drug ID
DR1648
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cytochrome P450 2C8 (CYP2C8)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trimethoprim. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Trimethoprim through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trimethoprim. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Trimethoprim through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trimethoprim. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Trimethoprim through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trimethoprim. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Trimethoprim through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Trimethoprim. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Trimethoprim through regulating the expression of P-glycoprotein 1 (ABCB1). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Trimethoprim. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Trimethoprim through regulating the expression of P-glycoprotein 1 (ABCB1). [4], [5]
References
Ref 1 Methylation of adenosine at the N(6) position post-transcriptionally regulates hepatic P450s expression. Biochem Pharmacol. 2020 Jan;171:113697. doi: 10.1016/j.bcp.2019.113697. Epub 2019 Nov 7.
Ref 2 Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51. doi: 10.1111/j.1742-7843.2006.pto_437.x.
Ref 3 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 4 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
Ref 5 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.